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Overview of Current Statin Use

Cardiovascular disease (CVD) is the leading cause of worldwide deaths, with mortality rates of approximately 235 per
100,000 inhabitants.1 In the vast majority of patients, CVD
is specifically attributed to atherosclerosis. While the development of atherosclerotic CVD (ASCVD) involves a variety
of biological processes and behavioral factors, high plasma
cholesterol levels are thought to play a primary causative
role.2 Thus, the preferred treatment of hypercholesterolemiainduced cardiovascular-associated diseases, which includes
ASCVD, involves the use of statins, which are highly effective
in lowering the cholesterol levels.3
Lovastatin became the first commercially available statin
medication in 1987 when it was given the United States Food
and Drug Administration (FDA) approval.4 Since then, the
use of statins has proven to be advantageous for the primary
prevention of CVD by reducing the risk and preventing the
onset of the disease.5 In addition, statins are often used for secondary prevention as they are effective in slowing disease progression and reducing cardiovascular-associated morbidities
and mortalities. In 2013, the American College of Cardiology
(ACC) and the American Heart Association (AHA) revised
the existing guidelines to reduce the risk of CVD.3 Since these

guidelines significantly expand the population of patients eligible for statin therapy, it is likely that statin use will dramatically increase.6 An increase in the use of statins is also
thought to arise from their cholesterol-independent (pleiotropic) effects, which have implications in a wide variety of
disease processes and thus may significantly broaden their
therapeutic use.7 Given that the patient population thought to
benefit from the use of statins will likely continue to increase,
it is imperative that factors associated with statin use such as
patient costs, their adverse effects (AEs), and their interactions with food and other drugs be thoroughly understood.
Furthermore, the effectiveness of statins in treating diseases
other than ASCVD, such as autoimmune/chronic inflammatory diseases, cancer, neurodegenerative disorders, stroke, and
bacterial and viral infections should be clearly established.
This review summarizes the most recent literature
regarding traditional statin therapy, their associated pleiotropic effects, and the current and emerging therapeutic applications of statins. Content within this review may be of value
for both the medical and research communities in guiding
efforts toward optimizing patient care and furthering our
understanding of issues pertaining to the use of statin therapy
for treating a plethora of disease states.
Lipid Insights 2016:9
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Current Therapeutic Applications of Statins

Goals of statin therapy. The prescribed use of statins for
preventing the onset of ASCVD or slowing its progression is
supported by decades of preclinical investigations and clinical
trials.3,8 Here, the relationships between high levels of lowdensity lipoprotein cholesterol (LDL-C) and the development
of ASCVD as well as the effectiveness of statin therapies for
enhancing patient health outcomes by lowering LDL-C levels
and reducing the overall incidence and prevalence of ASCVDassociated mortalities were clearly established. As a primary
prevention strategy, the use of statins allows high-risk patients
to maintain normal levels of LDL-C. In patients diagnosed
with ASCVD, statins are used as secondary prevention as they
are effective in significantly lowering the LDL-C levels and
reducing the risk of a fatal cardiovascular event. The categories
of LDL-C levels as defined by the National Heart, Lung and
Blood Institute are depicted in Table 1.
LDL and high-density lipoproteins. Lipoproteins are
particles that play a major role in transporting lipids, in circulation, such as cholesterol and triglycerides.9 Lipoproteins
are classified primarily according to their density and lipid
composition and consist of the following seven major types:
chylomicrons, chylomicron remnants, very low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL),
LDL, high-density lipoproteins (HDL), and lipoprotein(a). Chylomicrons carry dietary triglycerides and esterified
and unesterified cholesterol from the intestine to the liver.
While both VLDL and IDL are involved in the transport
of lipids from the liver to the peripheral tissues, VLDL
exports primarily triglycerides, whereas IDL exports both
triglycerides and cholesterol. LDL is highly enriched in

c holesterol, transporting the majority of cholesterol found in
the circulation. HDL transports both cholesterol and phospholipids but reverses the transport of the lipids by carrying
them from the peripheral tissues back to the liver where they
are recycled and excreted. The physiological function of lipoprotein-(a), an LDL particle, has not yet been defined.
LDL-C is often referred to as bad cholesterol due to its
close association with ASCVD, whereas HDL-C, because of
its role in reverse cholesterol transport and inverse relationship
with cardiovascular incidents, is known as good cholesterol.2
The causal relationship between LDL-C and ASCVD was
first established by using human genetic analyses.10 Here,
patients with familial hypercholesterolemia and elevated
LDL-C levels (due to loss-of-function mutations in the LDL
receptor) were found to develop early ASCVD. Furthermore,
patients expressing various forms of additional members of
the LDL pathway, such as protein convertase subtilisin/kexin
type 9 (PCSK9), exhibited low LDL-C levels, which corresponded to a reduced risk of developing ASCVD. In addition,
pharmacological analyses of the effectiveness of statins have
established a link between statin use and significant reductions in coronary events regardless of gender.11 Thus, use of
both genetic analysis and intervention strategies has firmly
established the importance of targeting LDL-C via the use of
statins as an effective approach for treating ASCVD.
Alternatives to statin use. While statins have proven to
be advantageous for lowering the LDL-C levels in the majority of individuals, some individuals fail to respond to treatment (statin resistant) or are prone to developing AEs (statin
intolerant).12 Patient’s response to statins varies widely with
reductions in LDL-C levels following the administration

Table 1. Classification of total cholesterol levels.
TOTAL CHOLESTEROL LEVEL  mg 
 dL 



CATEGORY

,200

Desirable

200–239

Borderline high

240#

High

LDL (BAD) CHOLESTEROL LEVEL  mg 
 dL 



LDL CHOLESTEROL CATEGORY

,100

Optimal

100–129

Near optimal/above optimal

130–159

Borderline high

160–189

High

190#

Very high

HIGH (GOOD) CHOLESTEROL LEVEL  mg 
 dL 



HDL CHOLESTEROL CATEGORY

,40

Major risk factor for heart disease

40–59

Transitioning to protective

60#

Considered protective against heart disease

Note: Adapted from Ref 184.
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of statins ranging from 5% to 70%. Patients who are statin
resistant do not achieve desired LDL-C target levels even
when a high dose of a potent statin is administered. Statin
resistance likely arises from a number of mechanisms including
polymorphisms in genes involved in cholesterol synthesis and
metabolism, such as 3-hydroxy-3-methyl-glutaryl-coenzyme
A reductase (HMGCR) and low-density lipoprotein receptor
(LDL-R), and those associated with statin pharmacokinetics, such as transporter proteins (eg, ATP-binding cassette
sub-family G member 2 [ABCG2] and SCLO1B1). Patients
who are statin intolerant typically exhibit sensitivity to
statin-induced myopathy and/or liver injury as indicated by
increases in liver enzyme activity. In both statin-resistant and
statin-intolerant patients, other avenues of treatment must be
explored.3 Alternatives to statin therapy include use of cholesterol absorption inhibitors and bile-acid sequestrants; however, they lack the potency of statins in their ability to lower
LDL-C levels. The need for more effective LDL-C-lowering
therapies, particularly for treating very high-risk patients, has
led to the development of PCSK9 inhibitors.13 However, their
relatively high cost and the limited data surrounding their
clinical effectiveness currently prohibits their wide-spread
use. Thus, current research and clinical efforts will continue to
focus on developing effective alternatives to statins in patient
populations where statin therapy is contraindicated.
Additional approaches, including specific dietary recommendations, such as fish and fish oil, and exercise, should be
also considered.14,15 For example, patients who altered their

diets and engaged in exercise programs of 10 miles of walking
or jogging per week showed a more substantial 14%–20%
decrease in LDL-C levels as compared to those who only
altered their diets.15 While a number of dietary regimens have
been designed to decrease LDL-C levels, their effectiveness
varies extensively. The most stringent diets, such as the AHA
Step-1 diet, and the Mediterranean diet, only elicit a reduction in
LDL-C levels by approximately 5%–9%.16,17 Diets such as the
Ornish diet have the ability to produce more impressive results,
decreasing serum LDL-C levels by approximately 17%.18
However, many of these diets may not be realistic in practice
as they vary considerably from the typical modern American
diet. The benefits reported with diet alone should be contrasted
with the benefits of statins as a routine secondary prevention
(35% cardiac event reduction). Diet and exercise should be
considered vital to the reduction of high cholesterol and prevention of cardiac events. However, diet and exercise may not
be able to lower LDL levels to less than 100 mg/dL. In these
instances, a pharmacologic statin therapy should be maintained with the continuation of diet and exercise.
Statin mechanisms of action. The current therapeutic
goal of statins involves the following mechanisms19 (as illustrated in Fig. 1). Statins inhibit HMGCR in hepatocytes.
HMGCR is the rate-limiting enzyme of the hepatic cholesterol synthetic pathway and converts 3-hydroxy3-methylglutaryl-coenzyme A (HMG-CoA) to melvalonic
acid—a precursor in the de novo cholesterol biosynthetic pathway.
Statins reversibly compete with the endogenous substrate,

Figure 1. Statin mechanism of action. (A) Statins attenuate HMG-CoA reductase enzymatic activity. (B) Intracellular cholesterol reduction. (C) SREBP
cleavage and translocation. (D) SREBP promotes LDL-R gene expression. (E) LDL-R gene transcribed and translated. (F) LDL-R density is increased on
cell surface. (G) LDL binding, endocytosis, and subsequent degradation. (H) Intracellular cholesterol increase toward cellular baseline. (I) Plasma LDL
levels decrease.
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HMG-CoA, for the active site within the reductase. Binding
of the statin to the active site of the enzyme confers a conformational change that attenuates the enzyme’s function.
Acting as competitive antagonists, the higher affinity statins
bind to the active site of the enzyme, thereby preventing binding of the lower affinity endogenous substrate, HMG-CoA
(Fig. 1A). The resultant conformational change and inhibition
of HMGCR decreases cholesterol production and reduces the
intracellular cholesterol stores of the hepatocytes (Fig. 1B).
In an effort to maintain homeostasis and counteract this
decline in intracellular cholesterol, a protease is triggered to
cleave the sterol regulatory element-binding protein (SREBP)
from its protein precursor in the endoplasmic reticulum. The
unbound SREBP is subsequently translocated to the nucleus
(Fig. 1C). In the nucleus, SREBP binds the sterol regulatory
element (SRE) located within the promoter elements of the
gene encoding LDL-R (Fig. 1D). Transcription of the LDL-R
gene is enhanced resulting in increased expression of LDL-R
mRNA and increased synthesis of LDL-R protein (Fig. 1E).
The hepatic LDL-R protein undergoes maturation and constitutive exocytosis intended for hepatocyte surfaces (Fig. 1F).
Free LDL-C binds to the newly synthesized LDL-R leading to endocytosis and subsequent lysosomal degradation of
LDL-C within the hepatocyte (Fig. 1G). The internalization
of LDL-C increases intracellular cholesterol levels and promotes a return to homeostatic levels of LDL-C (Fig. 1H). The
ultimate effect of this series of events is a reduction in circulating LDL-C levels—elicited in large part by the increase in
hepatic LDL-R cell surface density (Fig. 1I).
Use of statins for reducing the risk of ASCVD.
Recently, the ACC and AHA approved the revision of existing guidelines designed to reduce the risk of ASCVD that
were based on evidence generated from a series of randomized
controlled trials.3 While previous recommendations focused
on specific target levels of LDL-C, the new recommendations defined patient groups who would most likely benefit from
moderate- or high-intensity statin therapy. These groups have
been identified as follows:
i.

clinical ASCVD, ie, acute coronary syndromes, or a history of myocardial infarction, stable or unstable angina,
coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease of
atherosclerotic origin;
ii. primary elevations of LDL-C $190 mg/dL;
iii. age 40–75 years with diabetes and LDL-C 70–189 mg/dL;
iv. age 40–75 years with LDL-C 70–189 mg/dL and estimated 10-year ASCVD risk $7.5%.
As these guidelines are clinically implemented, it is predicted that 12.8 million additional individuals will now qualify
for statin therapy.6 As statin use continues to increase, a concern is raised that patients, as well as physicians, may become
over-reliant on pharmacological methods of controlling high
16
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cholesterol levels and disregard approaches such as lifestyle
changes that are beneficial for not only improving cardiovascular health 20 but also overall well-being. Lifestyle changes
such as the elimination of tobacco products, dietary modifications, weight management, exercise, and yoga have been
shown to be effective in reducing the risk of CVD. 21 Thus, it
is recommended that patients who qualify for statin therapy
would benefit the most from intervention strategies that would
include statin therapy coupled with a healthy lifestyle.22,23
Potential AEs associated with statin use. While statins,
in general, are well tolerated, AEs are reported and include
muscle pain and damage, increased blood glucose levels,
which may contribute to type 2 diabetes mellitus (T2DM),
hepatotoxicity, digestive problems, cognitive effects, and the
development of rashes or flushing.24 Of these AEs, those
impacting muscle, blood glucose levels, and liver function are
thought to be the most clinically relevant.
Muscle pain and damage. Statin-associated muscle symptoms (SAMS) are the most commonly reported AEs affecting
up to 30% of the patient population.25 SAMS typically present
as muscle pain, soreness, aching, stiffness, etc, and are often the
source of statin nonadherence or discontinuation. Clinically,
these symptoms can be defined as myopathy (muscle weakness), myositis (muscle inflammation), myonecrosis (elevated
muscle enzyme levels), rhabdomyolysis (severe myonecrosis
with myoglobinuria or acute renal failure) and myalgia (unexplained muscle discomfort which encompasses muscle aches,
soreness, etc). Mild myalgia occurs in 5%–10% of statin users
annually and is often intermittent. Life-threatening rhabdomyolysis occurs in only 0.001%–0.005% of patients or 1–5
of every 1000 statin users annually.24 Concerns related to the
risk of rhabdomyolysis have led to the removal of cervastatin
from the market and recommendations that patients who are
administered high doses of simvastatin (~80 mg) be closely
monitored.26,27 Statins are thought to adversely impact muscle
tissue by altering mitochondrial function and cellular energy
utilization as well as depleting coenzyme Q10 levels.25 Patients
who are at high risk for developing statin-induced muscle symptoms are often those with other comorbidities or who are coadministered other drugs as described in the following section.
Type 2 diabetes. The question of whether statin use significantly raises blood glucose levels and contributes to the
development of T2DM is complicated by the fact that high
LDL-C, ASCVD, and T2DM share common risk factors.28
Like ASCVD, behavioral risk factors of T2DM include a lifestyle devoid of physical activity, a high calorie diet saturated
with high trans-fat foods, cigarette smoking, and overweight/
obesity. Other contributing risk factors are socioeconomic and
include race/ethnicity, culture, and geographical location. 29
Thus, the likely use of statins by patients with T2DM may
be deleterious with respect to their T2DM-related conditions.
The diabetogenic effects of statins are thought to arise
from several mechanisms that converge on glucose regulation
and pancreatic beta cells, 30,31 including inhibition of isoprenoid
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synthesis and subsequent inhibition of glucose uptake by beta
cells, increased uptake of LDL leading to glucokinase inhibition
(hence blocking glucose conversion to pyruvate), and cytokineinduced overproduction of nitric oxide (NO) leading to beta cell
apoptosis. In addition, statins suppress ubiquinone and ATP
synthesis. These mechanisms may converge or they may in fact
be mutually exclusive, yet the ultimate effect rendered is one
that quells insulin release from beta cells.
A thorough review of the literature reveals the following three key themes that are important for understanding the
relationship that may exist between statin therapy and T2DM.
1.

2.

3.

Because of the mechanisms discussed earlier, statins may
raise blood sugar levels. Numerous population-based
studies have consistently reported that compared to
patients in the placebo group, a greater number of patients
receiving statin therapy were subsequently diagnosed
with T2DM.30–33 While there have been incident cases of
T2DM in longitudinal, randomized clinical trials within
a statin therapy group, there is less often a significant
difference in these incident cases occurring in the treatment group versus the control group. The findings of one
study revealed that 3% of the treatment group (rosuvastatin) developed T2DM while only 2.4% of the placebo
group developed the disease (P = 0.01).34 However, those
patients of the treatment group also had a significant
reduction in the risk of heart attack (54%), 48% reduced
risk of stroke, and 20% lower risk of mortality.
CVD risk is increased twofold to fourfold in patients
diagnosed with T2DM.35 In T2DM patients with normal LDL levels, statins may have a major role in preventing the long-term negative health effects often associated
with chronic T2DM. As in the first case, the long-term
benefits of a therapeutic statin regimen may outweigh
any undesirable effects.
Statins may have a diabetogenic potential through the
various mechanisms discussed earlier. While new-onset
T2DM is observed with all statins, 33 and associations
coupled from those observations, a causal relationship
cannot be implicated as numerous patients of the control
group (receiving a placebo) also in fact developed T2DM.
However, it has become widely accepted that this relationship is dependent on statin type and dose.28,36

It is thought that “statin therapy is associated with a
slightly increased risk of developing of diabetes.”35 However,
the risk is low, and when compared to the reduction in coronary events, the benefits of statin therapy outweigh the risk of
developing diabetes.
Liver function. Statin-induced hepatotoxicity is relatively
rare, and approximately 3% of patients who take statins develop
elevated transaminase levels, a marker of liver injury.37 The
increases in transaminase levels are typically temporary and
thought to be due to decreased cholesterol levels, increased

membrane permeability, and leakage of liver enzymes. In a
recent study, 22 out of 1188 cases of drug-induced liver injury
were attributed to statin use.38 Here, statin-induced liver
injury was primarily of mild-to-moderate severity and reversible and was typically observed after months or years of statin
use. Thus, as endorsed by the FDA, currently marketed statins
are associated with a very low risk of serious liver injury.
Patient-to-patient variability. Statin-induced AEs exhibit
considerable patient-to-patient variability due to factors such
as genetic polymorphisms, coadministration of drugs, sex,
body size, age, comorbidities, such as diabetes, kidney, and
liver disease, and the consumption of more than two alcoholic
drinks per day. Patients thought to be at increased risk for
developing AEs following statin use are described in Table 2,
including the elderly who have decreased drug metabolizing
capacity, increased exposure to multiple drug regimens, and
decreased muscle mass.39 Others at high risk include human
immunodeficiency virus (HIV) patients who are susceptible
to drug–drug interactions involving statins and antiviral
therapies.40 Specific statins that vary in their potencies and
pharmacokinetics are recommended and/or contraindicated in
these different patient populations.
The wide variability in statin plasma levels and statininduced responses in patients following a given statin dose
is linked to polymorphisms of genes involved in the import,
export, and metabolism of statins.41 Of particular interest
are cytochrome P450s (cytochrome P4502C9 [CYP2C9]
and cytochrome 3A4 [CYP3A4]) and drug transporters
(ie, solute carrier organic anion transporter family member
1B1 [SLCO1B1], which facilitates hepatic statin uptake and
the ABCG2 export pump). While CYP2C9 plays a key role in
metabolizing fluvastatin, CYP3A4 is of more importance in
metabolizing simvastatin and lovastatin. Patients expressing
various forms of CYP2C9, with reduced enzyme activity, are
more responsive to the LDL-C-lowering effects of fluvastatin.42
Similarly, patients expressing forms of CYP3A4 with reduced
enzyme activity are more responsive to the LDL-C-lowering
effects of simvastatin, atorvastatin, and lovastatin.43,44 Furthermore, patients who harbor allelic variations of both CYP2C9
and hepatic transporters (ie, OATP1B1) may be at high risk
for developing fluvastatin-induced myotoxicity.45 Finally, in
patients expressing a SLCO1B1 variant that is defective in
hepatic statin uptake, high statin plasma levels and elevated
risks of statin-induced myopathy have been observed.46 In fact,
a recent study reported that polymorphisms in SLCO1B1 and
ABCG2, which correspond to impaired transporter function,
accounted for 90% of the patient variability of rosuvastatin
plasma levels.47 Taken together, these studies are indicative
of the significant advances made in our understanding of how
polymorphisms in drug-metabolizing enzymes and transporters contribute to variations in patient’s response to statins.
As a result, the decision-making process involved in weighing the benefits and risks associated with statin use will likely
continue to improve.
Lipid Insights 2016:9
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Table 2. Differences in response to statin drugs among different patient populations.
PATIENT POPULATION

COMMENTS

SPECIFIC DRUG PRECAUTIONS

East Asian Ancestry185

· Asians taking statins have higher serum levels of
statins such as rosuvastatin than Caucasians

· Doses of rosuvastatin should be
decreased

Elderly39

· Decrease in muscle mass may increase risk of
myopathy
· As age increases, metabolizing enzymes may be
less functional, increasing AUC and the likelihood
of more drug–drug interactions

· Atorvastatin and rosuvastatin mildly
increase ethinyl estradiol and norgestrel,
used in some postmenopausal therapies

HIV40

· Warnings about the protease inhibitors and nonnucleoside reverse transcriptase inhibitors used
in highly active anti-retroviral therapy and statins,
specific to drugs metabolized by CYP3A4

· Atorvastatin and rosuvastatin may be
used with caution

Pediatrics186–188

· Dose-exposure-response relationships are poorly
defined in children and adolescents
· The ontogeny of drug metabolizing enzymes and
transporters likely impact statin plasma levels

· Statin use should be limited to children at
highest CVD risk
· Only the following statins are approved
for use: pravastatin at 8 years of age;
atorvastatin, fluvastatin, lovastatin, rosuvastatin, and simvastatin at 10 years of age

Familial hypercholesterolemia
(FH)188

· Potential for myopathic side effects, but risk is
similar to that of the general population

· Patient-dependent, three- to four-drug
combinations may be used
· Minor interactions between statins and
ezetimine

Chronic Kidney Disease
(CKD)189

· Statins do reduce cardiovascular events in CKD
(stages I–IV) but not for those with end-stage
renal disease and receiving hemodialysis

· Atorvastatin and fluvastatin are minimally
excreted by the kidneys

Statin use is associated with drug–food and drug–drug
interactions. Statins are involved in a variety of interactions
with food and other drugs and typically involve inhibition of
CYP2C9, CYP3A4, and transporters.48 Statin interactions
may be divided into the following two groups based on their
metabolic pathways: (1) those metabolized by CYPs; CYP3A4
(simvastatin, lovastatin, and atorvastatin), and CYP2C9
(ﬂuvastatin) and (2) those not metabolized by CYPs. While
both simvastatin and lovastatin are highly involved in drug–
drug interactions, for simplicity, the discussion below will be
limited to interactions involving simvastatin.
Statins and grapefruit. The most commonly reported
food–drug interaction involves grapefruit, which contains furanocoumarins, potent CYP3A4 inhibitors.49 Thus, ingestion
of grapefruit can impair a patient’s ability to metabolize drugs
like simvastatin, resulting in a significant increase in plasma
simvastatin levels. For example, the ingestion of grapefruit
juice (200 mL) can increase simvastatin plasma levels by more
than threefold.50 In some cases, the statin/grapefruit interaction can result in rhabdomyolysis.51 At this time, however, the
prevalence between severe, statin-induced AEs and the consumption of grapefruit in the general population is difficult to
ascertain.
Statins and other drugs. Drug–drug interactions involving simvastatin have been reported in patients concomitantly
administered drugs that are potent inhibitors of CYP3A4,
such as itraconazole, ketoconazole, amiodarone, cyclosporine,
ritonavir, and indinavir.48 Coadministration of simvastatin
with antifungals (itraconazole or ketoconazole) can result
in rhabdomyolysis and acute renal failure.52,53 Similar AEs
18
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may also arise upon coadministration of simvastatin with
amiodarone, an antiarrhythmic agent.54,55 In fact, the FDA
recommends that in patients taking amiodarone, the dose of
simvastatin should not exceed 20 mg/day. Concerns are also
expressed in patients treated with simvastatin and cyclosporine, an immunosuppressant.56,57 Here, the high prevalence of
rhabdomyolysis and acute kidney injury have triggered warnings that the coadministration of these two drugs should be
avoided. The AEs associated with cyclosporine use involve not
only its inhibition of CYP3A4 but also a number of influx and
efflux transporters.58 Finally, rhabdomyolysis has been reported
when patients were cotreated with simvastatin and HIV protease inhibitors such as ritonavir and indinavir.40 Because of
these reported events, the FDA has recommended labeling
changes for several statins (simvastatin, lovastatin, atorvastatin, and rosuvastatin) to include contraindications, cautions
against, or limited doses to reflect the risks for interactions
between these statins and HIV and HCV protease inhibitors.
The costs associated with the use of statins and other
cholesterol-lowering drugs. Between 2003 and 2012, statin
use in adults over the age of 40 years has increased from
18% to 26%.59 With the newer more stringent guidelines, this
percentage will increase making statins one of the most commonly prescribed medications in the United States. Depending on an individual’s economic status relative to the average
cost of the prescribed statin as well as constraints that may be
imposed by certain healthcare plans, statin use may impose a
significant financial burden. To illustrate this financial strain,
a comparison of the cost per day between the name brand and
generic equivalent is provided in Table 3. As shown, statins
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Table 3. Costs associated with the use of statins and other cholesterol-lowering drugs.
GENERIC
NAME

BRAND
NAMES

TYPICAL
DOSE

ESTIMATED COST
PER DAY (GENERIC)

ESTIMATED COST PER
DAY (BRAND NAME)

Atorvastatin

Lipitor

10 mg
20 mg

$2.26
$3.23

$5.65
$8.19

Fluvastatin

Lescol,
Lescol XL

40 mg (BID)
80 mg (SR)

$7.58
$7.00

$11.19

Lovastatin

Altoprev

40 mg

$2.16*

$21.00

Pravastatin

Pravachol

40 mg
80 mg

$1.16*
$2.16*

$6.61
$6.58

Simvastatin

Zocor

20 mg
40 mg

$2.29*
$2.19*

$7.39
$7.55

Rosuvastatin

Crestor

5 mg
10 mg

NA

$6.61
$6.50

Zetia

10 mg

NA

$7.12

Alirocumab

Praluent

75 mg every
2 weeks

NA

$40.00

Evolocumab

Repatha

140 mg every
2 weeks

NA

$38.63

Statins

Selective cholesterol absorption inhibitors
Ezetimibe
PCSK9 inhibitors

Note: *Indicates availability at a $4 Prescription Program location. Estimated Costs Per Day Refs 190 and 191.

that are currently available as generics, such as pravastatin
($1.16 per day), are relatively affordable as compared to those
sold as the brand name product of statins such as lovastatin
($21.00 per day). The newly marketed PCSK9 inhibitors
(alirocumab and evolocumab) are considerably more expensive, approximately $40 per day. Like other monoclonal antibodies, the relative high cost of PCSK9 inhibitors is attributed
to their complex production.
Comparison of individual statins. While statins are
often thought of as a singular entity with similar pharmacological effects, they differ significantly with respect to their
chemical properties, efficacy, safety, and the frequency and
type of side effects experienced. Extensive meta-analyses and
randomized trials have addressed this issue by comparing a
variety of different statins. Combining the results of these
studies, along with the cost of each drug as shown in Table 3,
demonstrates which statin may be the best choice for a particular patient.
The STELLAR study found that atorvastatin at doses
between 10 and 80 mg had the highest number of treatment
discontinuations due to AEs, followed by rosuvastatin, simvastatin, and pravastatin (although there was no 80 mg group
for pravastatin).60 These results coincide with the findings of
a meta-analysis that simvastatin and pravastatin appear to
be the most tolerable and safest of the tested statins.61 The
STELLAR study also found that rosuvastatin had the highest
average reduction in LDL-C from baseline at 51.06% (albeit
no reported data at an 80 mg dose), followed by atorvastatin
at 44.58%, simvastatin at 36.98%, and pravastatin at 24.7%.60

An additional meta-analysis of randomized trials, the
VOYAGER study, consisting of 32,258 patients, investigated various statin therapies and compared their impact
on the reduction in LDL-C and triglycerides in patients
with hypertriglyceridemia—a condition associated with an
increased risk of CVD. Here, rosuvastatin was found to reduce
LDL-C on average, by 52% at a lower dose (40 mg) than both
atorvastatin and simvastatin at a higher dose (80 mg), of which
showed a mean reduction of 49% and 43%, respectively.62
Narrowing the focus to specific potential AEs, interesting findings surrounding the development of T2DM and
SAMS, also referred to as muscle AEs, when comparing different statins are revealed. An analysis involving 246,955 individuals reported that the only AEs with higher odds ratios
(OR, 1.51) occurring with statin use compared to a control
were elevated transaminase levels and the development of
T2DM (OR, 1.09).61 In terms of individual statins, participants were more likely to develop T2DM when taking atorvastatin (OR, 1.17), followed by pravastatin and rosuvastatin
(OR, 1.16), simvastatin (OR, 1.10), and lovastatin (OR, 0.98).
Fluvastatin did not have a reported OR for T2DM; however,
in terms of transaminase elevation, there was a higher odds
(OR, 5.18) of occurrence, followed by atorvastatin (OR, 2.55),
lovastatin (OR, 2.03), rosuvastatin (OR, 1.59), simvastatin
(OR, 1.16), and pravastatin (OR, 1.00).
In addition, a relationship between the potency of statins
(as defined by the magnitude by which they reduce LDL-C
levels) and reported AEs has been identified in an analysis
representing 147,789 cases.63 Here, symptoms relating to
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rhabdomyolysis and less severe symptoms (ie, myalgia or joint)
were reviewed. Statins with the highest potency per milligram
appeared to have the highest AE relative risk. Thus, in a ranking whereby rosuvastatin was designated as 100% relative risk,
the less potent statins were ranked as follows: atorvastatin
(55%) . simvastatin (26%) . pravastatin (17%) . lovastatin
(7.5%) . fluvastatin (% not reported). An exception appears to
be fluvastatin, a low potent statin with a relatively high relative
risk of reported AEs (74%).
Ascertaining the best statin to be used for a particular patient is difficult because of factors associated with the
patient (the above mentioned patient-to-patient variabilities
in comorbidities, genetic polymorphisms, coexposure to other
drugs, etc) and those associated with the individual drug
properties (ie, lipophilicity, bioavailability, efficacy, potency,
and the prevalence of certain side effects). Pravastatin does
not appear to exert an LDL-lowering effect to the extent
imposed by the other statins, as reported in the STELLAR
and additional studies.60–62 However, it appears to be one of
the safest and cheapest options available, followed closely in
terms of safety and cost by simvastatin, which typically has a
low monthly generic copayment. While simvastatin appears to
be the best choice in terms of cost and safety, atorvastatin and
rosuvastatin may be more effective with respect to their ability to reduce cholesterol levels but harbor a higher probability
of exerting an AE and are also more expensive. Thus, it can
be seen that many factors need to be taken into consideration
when deciding which statin to administer; it is not a one-sizefits-all therapy, and instead, the therapy should be tailored to
the patient in order to accommodate for the aforementioned
differences yielding an optimal therapy.
It would be remiss to omit studies reporting findings that
vary significantly from other patient populations, globally. In
particular, two European studies, the PRIMO survey and
the STOMP study, retrospectively found that patients taking simvastatin, atorvastatin, or lovastatin may be at highest
risk of developing SAMS (18.2, 9.4%–14.9%).64,65 This variability may be due to the hydrophilic properties of fluvastatin
and pravastatin, which may limit their muscle penetration.64
However, we note that fluvastatin’s low association with
SAMS supports findings in previous studies that use of lower
potency statins may result in fewer AEs. It is evident that further research should be conducted in specific patient populations, with tightly controlled variables. Retrospective data can
be skewed by recall bias; therefore, prospective data should
be obtained through closely monitored randomized control
trials in order to compare specific AEs (such as SAMS) that
may result from the use of various statins in defined patient
populations.
Summary of statin use and ASCVD. Over the past
30 years, statins have been used as cholesterol-lowering
medications.4 Up to this point, this review has discussed
the intended mechanisms of action associated with statins,
drug–food interactions, and the use of statins as therapeutic
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agents for treating patients with ASCVD or those at risk of
developing ASCVD. The remainder of this review examines the pleiotropic effects associated with statins and their
potential role in abrogating the pathophysiological processes
involved in other disease states.

Emerging Therapeutic Applications of Statins

Therapeutic expansion of statin use. Recently, the
scope of statin therapy has expanded with the emergence of
evidence suggesting that due to pleiotropic effects of statins
that are not directly associated with their regulation of cholesterol levels, they may prove to be beneficial for treating a
number of diseases.7,66 The pleiotropic effects associated with
statins that may impact disease pathophysiology include their
modulation of immune responses, their enhancement of antiinflammatory processes, and their alterations of signaling
pathways that involve cholesterol intermediates. To date, the
multitude of diseases linked to the pleiotropic effects of statins
include multiple sclerosis (MS), inflammatory bowel diseases
(IBDs), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), chronic obstructive pulmonary disease (COPD),
cancer, strokes, Parkinson’s and Alzheimer’s diseases, bacterial infections, and HIV. The following section provides an
overview of our current understanding of how statins impact
the onset or progression of these diseases.
Mechanisms by which statins exert their pleiotropic
effects. The pleiotropic effects of statins were first reported
in 1995 when it was observed that the benefits of pravastatin
extended beyond those attributed to the expected lipid-lowering
effects of statin therapy.67,68 Further investigation revealed
that statins possessed novel cholesterol-independent effects,
which included stabilizing atherosclerotic plaques, enhancing
endothelial function, modulating immune responses, decreasing oxidative stress/inflammation, and inhibiting the thrombotic response.7,66 While statins may be able to modulate the
pathophysiology of a variety of disease states, their effectiveness is currently under considerable debate due to the diversity of the involved molecular mechanisms, the wide range of
statins’ pharmacokinetic properties, and issues surrounding
patient-to-patient variability.
Statins are thought to impact disease processes via
mevalonate-dependent and -independent mechanisms.7,69–72
Using a variety of cell types including immune,69 tumor,71
and endothelial72 cells, statins have been shown to alter fundamental cell processes by impinging on well-conserved, key
signaling molecules. In addition to the mechanisms described
below, those specific to the disease states under discussion are
outlined in the following sections.
The mevalonate-dependent mechanisms of statins. The
mevalonate-dependent mechanisms arise from statin inhibition of HMGCR activity, cholesterol biosynthesis, and protein
isoprenylation.69–72 The isoprenylation of proteins, a posttranslational modification, is required for membrane-associated
proteins to form covalent attachments, maintain appropriate
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subcellular localization, and engage in intracellular trafficking.
Key isoprenylated proteins are Ras, Rho, and Rac—critical
GTPases that regulate a variety of biological processes involved
in determining cell proliferation, fate, and morphology.
The mevalonate-independent actions of statins. The
mevalonate-independent effects of statins involve their inhibition of a variety of signal molecules including lymphocyte
function-associated antigen 1 (LFA-1) and intercellular adhesion molecule 1 (ICAM-1).69,70,72 LFA-1 modulates leukocyte
trafficking and T cell activation, whereas ICAM-1 sustains
leukocyte adhesion and facilitates migration. Other mevalonate-independent actions of statins include their inhibition of
signal transduction molecules (v-akt murine thymoma viral
oncogene homolog [AKT], extracellular signal-regulated
kinase [ERK]/mitogen-activated protein kinases [MAPK]
and janus kinase (JAK)/signal transducer and activator of
transcription [STAT]) and transcription factors involved in
mediating proinflammatory responses (nuclear factor-kappa
B [NF-κB], activator protein 1 [AP1], histone deacetylase
[HDAC], STAT1, STAT3, and STAT4).69,70 In addition,
statins activate anti-inflammatory responses by enhancing the
activity of transcription factors such as Kruppel-like factor 2
(KLF2) and peroxisome proliferator-activated receptors
α and β, which suppress NF-κB and AP1 gene activation.
The extent to which the mevalonate-dependent pathway versus mevalonate-independent pathway contributes
to the pleotropic effects of statins has undergone increased
scrutiny.69,70 Early interest in the mevalonate-independent
pathway was stimulated by the observation that statins are
inhibitors of LFA-1 and block its ability to interact with
ICAM-1 and thereby inhibit T-cell migration.73,74 However,
since excess mevalonate can reverse a statin’s ability to inhibit
T cell proliferation and function, the importance of statin
inhibition of LFA-1 is questionable.75,76 Thus, the extent to
which mevalonate-dependent pathway versus mevalonateindependent pathway mediates the pleiotropic and antiinflammatory actions of statins requires further investigation.
Stains, NO signaling, and cell fate decisions. Importantly,
statins also impact vascular and immune functions via altered
NO signaling leading to improved vascular function, inhibition of leukocyte chemotaxis, and downregulation of leukocyte adhesion and migration at the vascular wall.69,72 Statin
modulation of NO bioavailability involves the following three
major mechanisms: direct activation of endothelial nitric oxide
synthase (eNOS) activity via activation of protein kinases
(AMP-activated protein kinase [AMPK], AKT, and protein
kinase A [PKA]), increased eNOS expression via reduction
in the Rho/Rho-associated protein kinase (ROCK) pathway,
and stabilization of eNOS mRNA and reestablishment of
eNOS coupling via upregulation of guanosine triphosphate
cyclohydrolase (GTPCH).77
The current interest in the pleiotropic effects of statins
has focused on their ability to modulate cell fate decisions,
in particular the proliferation and apoptosis of tumor cells71

and the differentiation and proliferation of T cells.69,70 Statins
inhibit cell proliferation by inhibiting Ras and Rho proteins
and stabilizing the levels of cell cycle proteins (p21 and p27).71
Furthermore, statins induce apoptosis by upregulating proapoptotic proteins (ie, Bax) and downregulating antiapoptotic proteins (ie, Bcl-2). With respect to T cells, statins block
T cell activation, migration, infiltration of the target organ,
differentiation and proliferation, and the ability to secrete proinflammatory cytokines.69,70 Given that the improper type 17
helper cells (TH17)/regulatory T cells (TREG) balance contributes to autoimmune and inflammatory diseases, increasing
efforts are ongoing to devise therapeutic strategies to restore
this balance.78
Do statins inhibit the onset or progression of autoimmune and chronic inflammatory diseases? In many chronic
disease states, the inflammatory response is absconded from
its protective role (eliminating a disease stimuli) to a deleterious role of damaging tissue and causing organ failure.78,79
In some diseases, such as MS, the protective versus deleterious
switch occurs when self-recognizing antibodies and autoimmunity develop. In other diseases, like IBD, it occurs when loss
of immune tolerance and tissue homeostasis are met with an
overly aggressive immune response.76 The immune response
triggered by these initial events has been frequently described
as dysfunctional or exaggerated and results in chronic and often
episodic inflammatory conditions. Regardless of the initial
pathological events, the progression of autoimmune/chronic
inflammatory diseases typically involves an increase in the
severity and frequency of inflammatory episodes (or disease
flares), resulting in persistent exposure to the inflammatory
milieu causing necrosis and extensive tissue damage. In the
majority of patients, an overabundance of cells that exert proinflammatory responses (eg, TH1, TH 2, and TH17) and a lack
of those mediating anti-inflammatory responses (TREG) are
observed.78 Thus, the ability of statins to alter this imbalance
of TH1, TH 2, and TH17 cell populations versus TREG cell populations is of particular interest.74
Statins and MS. The pathology of MS involves TH1/TH17
and cytotoxic CD8 T cells, which contribute to proinflammatory conditions and demyelination of axons in the central
nervous system (CNS).80 As the disease progresses, the neurons degenerate, resulting in the neurological decline associated with MS. The first clinical manifestation, clinically
isolated syndrome, may or may not develop into MS.81 Once
diagnosed, MS typically presents as one of the following four
types: primary progressive, secondary progressive, relapsing
remitting (RRMS), and progressive. RRMS, the most common clinical presentation, involving approximately 80% of all
cases, often develops into nonrelapsing secondary progressive
MS. In animal models of MS, statins inhibit myelin antigen
presentation, block the activation and differentiation of T cells,
and reduce the recruitment of leukocytes.80 The neuroprotective effect of statins may also involve their ability to enhance
oligodendrocyte differentiation, reduce oxidative damage,
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improve vascular function by regulation of NO production,
inhibit coagulation, promote angiogenesis, and modulate the
peripheral inflammatory response.
In key randomized clinical trials, statin treatment was
most beneficial to patients with secondary progressive MS
reducing the rate of atrophy by as much as 43%.82 In patients
with RRMS, however, conflicting results have been reported,
which is attributed to either the statin dose or complications
that may have arisen from their cotreatment with conventional anti-inflammatory agents, either interferon β (IFNβ)
or methylprednisone.82–87 As a result, uncertainty exists as
to whether or not the coadministration of statins with either
IFNβ or methylprednisone is therapeutically beneficial to
patients with RRMS. A recent meta-analysis of eight randomized clinical trials has reviewed the effectiveness of statin
therapy (simvastatin or atorvastatin) in MS patients.88 With
respect to RRMS, statin therapy used as either a monotherapy
or in combination with IFNβ was not found to be therapeutically beneficial. With respect to clinically isolated syndrome,
statins, administered as a monotherapy, were not convincingly
beneficial. However, with respect to secondary progressive
MS, some benefit may be achieved from the use of statins.
Statins and IBD. IBD, composed of Crohn’s disease and
ulcerative colitis, involves a variety of genetic and environmental
factors, a dysregulated immune response mounted against the
intestinal microbiota and chronic intestinal inflammation.89
The majority of studies performed using IBD-relevant animal
models have found that statin administration alleviates most
of the observed inflammatory symptoms.90 In patient populations, statin exposure has been associated with a significant
decrease in IBD onset, particularly in older (.60 years of
age) patients.91 Furthermore, in patients diagnosed with IBD,
statin use was associated with a reduced use of oral glucocorticoids, implying that statins reduced the severity of their disease conditions.92 Other studies have found that IBD patients
who were treated daily with statins (atorvastatin) had significantly reduced plasma levels of markers of systemic inflammation (ie, C-reactive protein).93,94
Statins and RA. RA is characterized by chronic inflammation of the joints, synovial hyperplasia, bone destruction,
joint deformity, and systemic inflammation.95 Patients with
RA are at an increased risk of mortality, as much as 50%, due
primarily to increases in CVDs.96,97 A recent meta-analysis
involving 992 RA patients demonstrated that statin use significantly decreased serum levels of inflammatory markers.98
Furthermore, patients taking statins have a reduced incidence
of RA,99 and in those taking simvastatin and atorvastatin,
a reduction in markers indicative of both RA and CVD has
been reported.100,101 Despite these promising early studies,
further investigation is needed to supplement the notion of a
statin as an effective therapy to treat RA.
Statins and SLE. SLE is an autoimmune disease that
involves aberrant B cell and T cell signaling and dysregulated apoptosis.102,103 The cellular debris that accumulates
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provides a source of autoantigens, which contributes to
chronic inflammation, formation of immune complexes in
specific organs, and organ failure. SLE patients are at high
risk for developing CVD, which is thought to arise from a
shared pathogenesis.104 However, randomized controlled trials have failed to demonstrate an effect of statin therapy on
SLE disease activity, despite observed reductions in serum
C-reactive protein levels.105 Other studies indicate that in
SLE patients with hyperlipidemia, statins may reduce the risk
of mortality.106 In some patients, however, the development
of autoimmune reactions has been noted, particularly when
either simvastatin or atorvastatin was administered.107,108
Autoimmune reactions involving these second-generation
statins may arise from their proapoptotic activities as well as
a statin-induced shift from TH1 to TH 2 immune responses,
enhanced B cell reactivity, and the production of pathogenic
autoantibodies. Thus, use of statins for treating SLE holds
promise, but the possible development of autoimmune reactions in SLE patients requires further scrutiny.
Statins and COPD. The pathology of COPD, an irreversible and progressive obstruction of airflow, also involves an
abnormal inflammatory response.109 While statins have been
considered for use in treating COPD, current guidelines do
not recommend the use of statins to prevent acute disease
exacerbations.110 The basis for these guidelines stems from
the discrepancy between results obtained from retrospective cohort studies indicating a beneficial effect of statins in
COPD patients and those from randomized clinical studies,
which have failed to confirm these findings.109–112
Do statins inhibit the onset and/or progression of
cancer? The idea that statins may exert anticancer effects
arose in part from reports that statin use was associated with
a significant reduction in colorectal cancer incidences113 and
a reduction in mortality associated with 13 different cancer
types.114 However, as discussed in more detail below, epidemiological and clinical studies have thus far failed to consistently
substantiate claims that statins are effective chemopreventive/chemotherapeutic agents but instead have underscored
the complexities associated with the development and treatment of human cancers. Our analysis of statins and cancer
will be limited to cancers of the colon, breast, and prostate
as these are among the top five most commonly diagnosed
cancers worldwide.115 Furthermore, the analyses of the impact
of statins on the onset, progression, and cancer-specific mortality of colorectal, breast, and prostate cancers are relatively
extensive. The steroid responsive cancers (breast and prostate)
are of particular interest as both the disease etiology and therapy hinge on the activities of estrogen and androgen, respectively, which may be modulated by statins within the breast
or prostate tumor cell. By comparing and contrasting the
impact of statins on the onset and progression of these three
cancer types, we aspire to identify commonalities and major
mechanistic pathways that may be relevant to the majority of
human cancers.
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Statins as potential chemopreventive agents. The question of
whether statin use prevents the onset of colorectal, breast, or
prostate cancers is confounded by the contradictory nature
of the reports from observational studies. For example, the
impact of statin use on colorectal cancer incidence has been
widely studied for more than a decade.116 Despite this, a recent
meta-analysis representing more than 8 million patients and
employing a variety of methodological approaches has failed to
convincingly and consistently demonstrate that long-term use
of statins prevents the onset of colorectal cancer. Perhaps more
troubling are reports indicating that statin use may increase
the risk of colorectal cancer.117 Similar contradictory findings
have been reported with respect to the impact of statin use
on breast cancer incidences where an analysis of more than
77,000 women found that the risk of developing breast cancer
was not associated with statin use regardless of use duration.118
Others report that extended statin use is associated with an
increased risk of developing breast cancer.119 With respect to
prostate cancer, the evidence pertaining to statin use is similarly contradictory. Some studies report that statin use is not
associated with the risk of developing prostate cancer.120,121
Others report that statins may decrease the risk of developing
low-grade, early-stage prostate cancer but not advanced stage
prostate cancer.122 In contrast, yet others report that statin use
was not associated with a decrease in overall risk of prostate
cancer but rather a decrease in the risk of developing advanced
prostate cancer.123,124
In addition to preventing the onset of cancer, statins
have potential for inhibiting cancer metastasis and improving
patient survival. Thus far, reports from phase II/III clinical
trials indicate that statin use does not improve progressionfree survival of patients who have been diagnosed with metastatic colorectal tumors.125,126 With respect to breast cancer,
some studies have found no association between statin use and
breast cancer mortality,127 while others suggest that statins
may decrease breast cancer mortality128,129 particularly, if the
most lipophilic statin, simvastatin, had been administered.130
However, reports focused on prostate cancer are more optimistic with some studies suggesting that statins attenuate
prostate cancer progression131,132 and mortality.133–135
A number of issues may contribute to the contradictions surrounding the question of whether statins are effective
anticancer agents. First, is the timing of the events associated
with the development of a tumor relative to the duration of
statin use. The majority of human tumors are likely caused
by a series of mutational events that sequentially occur over
a span of 20–30 years depending on the affected genes and
involved cellular processes.136 Thus, a statin may effectively
modulate the relatively modest changes in cellular processes
that form within a cell of an emerging tumor (ie, within years
1–10 of tumor development) but may lack potency in overcoming the plethora of metabolic and cellular processes that
exist within a fully developed tumor at the end of this 20to 30-year period. Second, the role of cholesterol in tumor

development is undefined and may present an indication bias
when statins are used to treat high cholesterol.137 The available
evidence indicates that high blood cholesterol (an indicator
for the administration of statins) may be associated with a
decrease in colorectal cancer incidence137 but an increase in
prostate cancer incidence.138 Third, cancer is a highly heterogeneous disease composed of distinct subtypes that likely
determine a patient’s tumor development and response to a
particular drug therapy or chemopreventive agent.139
It is possible that only a specific tumor subtype can
respond to the anticancer effects of statins. With respect to
colorectal tumors, molecular subtyping aligns with tumor
progression involving activation of oncogenes (ie, Kirsten rat
sarcoma viral oncogene homolog [KRAS]) and inactivation of
tumor suppressor (ie, adenomatous polyposis coli [APC]) and
DNA repair genes. In IBD patients, tumor development is
also influenced by the chronic inflammatory conditions within
the colon.140 With respect to breast cancer, molecular subtyping relies on tumor expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor
2 (HER2). Ongoing molecular characterization of prostate
cancer includes aberrant androgen receptor signaling, as well
as genes such as ETS protooncogene (ETS), KRAS, phosphatidylinositol 3-inositol (PI3K)/AKT, phosphatase and tensin homolog (PTEN), and tumor suppressor p53 (TP53).141
Studies examining the impact of statin use on breast cancer
subtypes indicate that statins may increase142 or decrease143 the
risk of developing ER-negative breast cancers or may increase
the risk of developing PR-negative breast cancer.144 However,
others report that statin use is not associated with incidence
regardless of the breast cancer subtype that has developed.145
Whether or not statins impact specific subtypes of colorectal
and prostate tumors is yet to be determined.
Putative chemopreventive mechanisms of statins. Efforts
focused on identifying patients most likely to respond to the
anticancer effects of statins have uncovered a few important
underlying genetic and mechanistic events. For example,
patients who harbor a form of HMGCR that is less effective at
binding statins appear to be less responsive to a statin’s ability
to reduce the onset of colorectal cancer.146 Furthermore, in
patients undergoing androgen deprivation therapy, the ability
of statins to delay prostate tumor progression appeared to
involve statin interaction with solute carrier organic anion
transporter family member 2B1 (SLCO2B1).131 It is proposed
that by interacting with the SLCO2B1 transport protein,
statins competitively displace androgens, thereby preventing
their entry into the tumor cell and inhibiting their protumorigenic activities. Similar events may occur in breast cancer
patients and thereby alter their response to antiestrogens,
since estrone 3-sulfate, a component of the estrogen pool, is
also subject to SLCO2B1 transport.147
Attempts to identify appropriate biomarkers to assess the
chemotherapeutic effectiveness of statins include a clinical
trial, wherein a relatively high statin dose (ie, 80 mg/day)
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resulted in a decreased tumor expression of Ki67, a marker
of proliferation, and a corresponding decrease in serum
cholesterol levels.148 Additional suggested biomarkers include
high sensitivity C-reactive protein, estrone sulfate,149 and
proteins involved in apoptotic pathways.150 These types of
clinical trials are invaluable for improving our ability to predict how statins may alter the progression of breast cancer,
determine the extent to which individual breast cancer
patients may respond to the statin administration, and identify appropriate biomarkers for examining their effectiveness.
Whether or not these findings are applicable to other cancer
types remains to be seen.
Should statins be used to prevent strokes. Strokes occur
when blood flow to the brain is restricted, resulting in neuronal cell death.151 This cell death often leads to the symptomatic dysfunction of parts of the body controlled by the
affected brain regions. Strokes occur in the following two
main forms: ischemic (more common) and hemorrhagic. The
former is caused by a deficiency in blood flow characterized by
blockage, whereas the latter is caused by damaging pressure
produced by the bleeding of arterial blood vessels in the brain.
Ischemic stroke can also be further subdivided into the following two causal categories: embolic stroke and thrombotic
stroke. Thrombotic stroke is often associated with hypercholesterolemia and atherosclerosis and is caused by the formation
of a blood clot in an artery that supplies the brain.152
While statins have been considered for use in preventing the onset and severity of stroke, an analysis of the literature has produced weak and often inconsistent associations
between stroke and hypercholesterolemia.153 The inherent
heterogeneity in the disease may be the likely culprit of these
inconsistencies, as stroke has various etiologies.154 However,
it has been shown that statin-induced reduction in cholesterol
concentrations decreases the risk of stroke in high-risk patient
populations (ie, those with established coronary artery disease,
hypertension, diabetes, or a high vascular risk).154,155 A metaanalysis155 revealed that each 1 mM decrease in LDL cholesterol compared to a 21.1% overall reduction in the relative risk
for stroke. These results were mirrored by an additional study
showing a consistent 17%–21% reduction in incident stroke
risk when patients were put on a statin regimen.154
A multitude of recent experimental studies156–158 have
pointed to a decrease in mortality risk with statin therapy
when rendered both before and after the onset of stroke.159
This decline in mortality risk may be attributed to the neuroprotective and neurorestorative effects of statins during
the onset of an ischemic stroke and after, respectively.160–164
Furthermore, studies have shown that statin treatment has led
to improvement in short-term and long-term poststroke quality of life and survival—these results may even be modulated
by the stroke severity.153,156,160–164 However, due to the inconclusive and discordant nature of some reports, more research
must be conducted to validate the efficacy of statin therapy on
stroke prevention and recovery.
24

Lipid Insights 2016:9

Should statins be used to treat neurodegenerative
disorders? The use of statins to treat a number of neurodegenerative disorders, including Parkinson’s and Alzheimer’s
diseases, has also been reported.165,166 The pathophysiology
of Parkinson’s disease involves aggregation of alpha-synuclein
(α-S), a presynaptic, neuronal protein, which normally binds
to plasma membranes.167 In addition, high cholesterol levels
are implicated in disease progression and the use of statins in
animal models of Parkinson’s disease can reduce α-S aggregation and neuropathology.168 While some epidemiological
studies report that statin use may reduce the risk of Parkinson’s
disease,169 others imply that these protective effects are not
observed after adjusting the results for cholesterol levels.170
With respect to Alzheimer’s disease, high cholesterol
levels are associated with disease progression and the appearance of plaques, a key characteristic of Alzheimer’s disease.171
Despite promising results performed in animal models, the
results from two randomized clinical trials failed to demonstrate a difference in cognitive decline in patients who were
receiving statin treatment (simvastatin and/or pravastatin) for
at least 12 months as compared to the placebo control.172 Due
to inconclusive evidence, statins and their role in the prevention and treatment of neurodegenerative diseases require further investigation.
Should statins be used to treat bacterial infections? The
ability of statins to modulate the immune and inflammatory
responses may abrogate the pathogenesis of diseases, such as
tuberculosis, sepsis, listeriosis, and infections of the host by
a bacterial entity.173–177 With respect to bacterial infections,
statins appear to modulate the expression of extracellular receptors involved in the attachment and uptake of certain bacteria. As shown in studies using Pseudonomas aerginousa, statins
can impede bacterial motility and biofilm production as well
as attenuate the secretion of proinflammatory cytokines.176
Additional studies have been performed on several bacterial
species, which have yielded consistent results.173,175 For example, a study involving Mycobacterium tuberculosis, the causative
agent of most cases of tuberculosis, found that statins counteracted the bacteria’s ability to inhibit immune cell maturation.173 Similarly, when statins were administered prior to
infection with Listeria monocytogenes, the ability of the bacteria to escape phagosomes was inhibited, which diminished
their evasion of the immune response.175 Although the precise
mechanisms by which statins modulate the immune system
in response to bacterial infections are unknown, these studies
highlight the potential for the use of statins in the prevention
and treatment of bacterial infections.
Should statins be used to treat patients with HIV-1?
Antiviral therapy is used extensively to treat individuals with
HIV-1.178 While pharmacologic agents, such as HIV-1 protease and nucleoside reverse transcriptase inhibitors, are effective
at suppressing viral replication, their use is often accompanied by abnormal fat redistribution, peripheral fat wasting,
central adiposity, and elevated cholesterol and triglyceride
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concentrations.179 Thus, statins are often administered to HIV
patients to reduce their cholesterol levels and normalize their
body composition.180,181 Statins may also reduce HIV-1 infection, presumably via inhibition of protein prenylation, downregulation of Rho activity, and rearrangement of the actin
cytoskeleton, which prevents HIV-1 from gaining entrance to
the host cells.182,183 In a recent clinical study, statin administration to patients chronically infected with HIV-1 significantly reduced serum viral RNA loads. However, upon
discontinuation of statin therapy, viral load rebounded. These
data imply that future clinical studies should be conducted to
further assess the use of statins as antiviral agents.

Conclusions

To fully understand whether statins display desirable pleiotropic effects and/or should be used as novel or adjunct therapies
to treat various diseases—aside from hypercholesterolemia—a
number of steps should be considered. First, the patients who
are most likely to positively respond to the desired effect of
statins must be identified. Second, the most effective dose,
duration of use, and statin drug entity to be used must be
clinically established. Third, biomarkers accurately reflecting
the pleiotropic actions that are clearly indicative of a patient’s
response to the statin and are specific for the disease state of
interest should be identified. Successful completion of these
endeavors would then culminate in randomized clinical trials
designed to evaluate the purported efficacy of various off-label
effects of statins.
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